Benzonatate has a surprisingly thin evidence base for a drug that’s been prescribed since 1958. While many patients report subjective relief from cough, clinical studies have produced mixed and often underwhelming results. A 2023 systematic review found that the existing evidence for benzonatate’s effectiveness is so limited that it likely wouldn’t meet current FDA approval standards.
What the Clinical Evidence Actually Shows
The research on benzonatate is, to put it plainly, not great. A comprehensive systematic review published by Costantino and colleagues in 2023 found that the original studies supporting its approval involved very small populations and limited clinical settings, with high degrees of bias related to sample size, data collection, and study design. The authors concluded there is a “substantial limitation within existing evidence” for the drug’s effectiveness.
Individual studies tell a similarly complicated story. In a capsaicin-induced cough study (Gayle et al., 2008), benzonatate alone did not significantly suppress cough sensitivity compared to placebo. Guaifenesin, an expectorant found in many over-the-counter cold products, did reach statistical significance on its own. However, the combination of benzonatate plus guaifenesin suppressed cough more than either drug alone.
A more recent prospective cohort study by Ebell and Merenstein (2025) found no association between receiving benzonatate and improvements in cough duration, cough severity, or the need for follow-up visits. An Oregon drug review similarly concluded there was “insufficient evidence of efficacy” for benzonatate, noting that results across three low-quality studies were mixed: one placebo-controlled study was negative, while two others found it more effective than opioid-based cough suppressants.
One retrospective review (Morrison & Schindler, 2011) did find that among patients who completed a trial of benzonatate, 57% reported improvement in their cough. That’s a meaningful number, but it comes from self-reported data without a placebo comparison, which makes it hard to separate genuine drug effect from placebo response or natural cough resolution.
How Benzonatate Works
Unlike most cough suppressants, which act on the brain’s cough center, benzonatate works at the source. It numbs the stretch receptors in your airways, lungs, and the lining around your lungs. These receptors normally detect irritation or expansion and trigger the cough reflex. By dampening their activity, benzonatate reduces the signal that tells your body to cough. Think of it like a local anesthetic for the inside of your respiratory tract.
The standard adult dose is one 200 mg capsule three times daily as needed, with a hard maximum of 600 mg per day. Onset of action is typically reported at 15 to 20 minutes, with effects lasting several hours per dose.
How It Compares to Other Cough Suppressants
Dextromethorphan, the active ingredient in most over-the-counter cough medicines, has a stronger evidence base. A review of six studies found it produced measurable reductions in both cough severity and cough frequency compared to placebo. Benzonatate has no equivalent body of consistent positive evidence.
That said, the comparison isn’t entirely straightforward. Dextromethorphan works on the brain, while benzonatate works on the airways themselves. Some clinicians prescribe benzonatate specifically for patients who haven’t responded to other options, or when a cough seems driven by airway irritation rather than a central reflex. The two drugs also have different side effect profiles, which can matter when choosing between them.
Why Capsules Must Be Swallowed Whole
This is one of the most important practical details about benzonatate. The capsules are filled with liquid, and if you chew, crush, dissolve, or suck on them, the numbing agent releases directly into your mouth and throat. This rapidly anesthetizes the tissue lining your mouth and airway, which can cause choking. In severe cases, it has triggered bronchospasm (sudden airway tightening), laryngospasm (vocal cord spasm that blocks airflow), and cardiovascular collapse. These are not theoretical risks. Always swallow benzonatate capsules whole with water.
This same property makes benzonatate particularly dangerous for children. The liquid-filled capsules can look like candy, and even one or two capsules can cause life-threatening toxicity in a small child. The drug is not approved for children under 10.
Common Side Effects
Most people tolerate benzonatate without serious problems. The more commonly reported side effects include drowsiness, dizziness, headache, nausea, constipation, and a sensation of numbness in the chest (which is essentially the drug doing what it’s designed to do). Allergic reactions are rare but can be severe, particularly the hypersensitivity reactions linked to local anesthetic release from improperly handled capsules.
The Bottom Line on Effectiveness
Benzonatate occupies an unusual position in medicine: widely prescribed, yet poorly supported by modern evidence standards. Some patients find it genuinely helpful, and the 57% improvement rate from one retrospective study suggests it does something for a meaningful portion of people who try it. But the lack of large, well-designed trials means it’s impossible to say with confidence how much of that benefit is the drug itself versus placebo effect or natural cough resolution. If you’ve been prescribed benzonatate and it’s reducing your cough, that’s a reasonable reason to continue it. If it hasn’t helped within a few days, there’s no strong evidence suggesting you should wait longer for it to kick in.